Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study.


Journal

Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760

Informations de publication

Date de publication:
01 09 2022
Historique:
pubmed: 25 3 2022
medline: 9 9 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

Facial Emotion Recognition is a key domain of social cognition associated with psychotic disorders as a candidate intermediate phenotype. In this study, we set out to investigate global and specific facial emotion recognition deficits in first-episode psychosis, and whether polygenic liability to psychotic disorders is associated with facial emotion recognition. 828 First Episode Psychosis (FEP) patients and 1308 population-based controls completed assessments of the Degraded Facial Affect Recognition Task (DFAR) and a subsample of 524 FEP and 899 controls provided blood or saliva samples from which we extracted DNA, performed genotyping and computed polygenic risk scores for schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MD). A worse ability to globally recognize facial emotion expressions was found in patients compared with controls [B= -1.5 (0.6), 95% CI -2.7 to -0.3], with evidence for stronger effects on negative emotions (fear [B = -3.3 (1.1), 95% CI -5.3 to -1.2] and anger [B = -2.3 (1.1), 95% CI -4.6 to -0.1]) than on happiness [B = 0.3 (0.7), 95% CI -1 to 1.7]. Pooling all participants, and controlling for confounds including case/control status, facial anger recognition was associated significantly with Schizophrenia Polygenic Risk Score (SZ PRS) [B = -3.5 (1.7), 95% CI -6.9 to -0.2]. Psychosis is associated with impaired recognition of fear and anger, and higher SZ PRS is associated with worse facial anger recognition. Our findings provide evidence that facial emotion recognition of anger might play a role as an intermediate phenotype for psychosis.

Sections du résumé

BACKGROUND AND HYPOTHESIS
Facial Emotion Recognition is a key domain of social cognition associated with psychotic disorders as a candidate intermediate phenotype. In this study, we set out to investigate global and specific facial emotion recognition deficits in first-episode psychosis, and whether polygenic liability to psychotic disorders is associated with facial emotion recognition.
STUDY DESIGN
828 First Episode Psychosis (FEP) patients and 1308 population-based controls completed assessments of the Degraded Facial Affect Recognition Task (DFAR) and a subsample of 524 FEP and 899 controls provided blood or saliva samples from which we extracted DNA, performed genotyping and computed polygenic risk scores for schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MD).
STUDY RESULTS
A worse ability to globally recognize facial emotion expressions was found in patients compared with controls [B= -1.5 (0.6), 95% CI -2.7 to -0.3], with evidence for stronger effects on negative emotions (fear [B = -3.3 (1.1), 95% CI -5.3 to -1.2] and anger [B = -2.3 (1.1), 95% CI -4.6 to -0.1]) than on happiness [B = 0.3 (0.7), 95% CI -1 to 1.7]. Pooling all participants, and controlling for confounds including case/control status, facial anger recognition was associated significantly with Schizophrenia Polygenic Risk Score (SZ PRS) [B = -3.5 (1.7), 95% CI -6.9 to -0.2].
CONCLUSIONS
Psychosis is associated with impaired recognition of fear and anger, and higher SZ PRS is associated with worse facial anger recognition. Our findings provide evidence that facial emotion recognition of anger might play a role as an intermediate phenotype for psychosis.

Identifiants

pubmed: 35325253
pii: 6553131
doi: 10.1093/schbul/sbac022
pmc: PMC9434422
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1104-1114

Subventions

Organisme : Medical Research Council
ID : HEALTH-F2-2009-241909
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101272/Z/12/Z
Pays : United Kingdom

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

Références

Arch Gen Psychiatry. 1991 Aug;48(8):764-70
pubmed: 1883262
Trans Am Neurol Assoc. 1968;93:38-42
pubmed: 5711050
Psychol Med. 2015 Apr;45(6):1135-44
pubmed: 25395075
Psychiatry Res. 2018 Aug;266:147-151
pubmed: 29864614
Neurosci Lett. 2016 Oct 28;633:47-54
pubmed: 27637386
Nat Med. 2016 Nov;22(11):1214-1219
pubmed: 27783064
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
J Int Neuropsychol Soc. 2019 Feb;25(2):165-173
pubmed: 30466500
Psychiatry Res. 2014 May 15;216(2):206-12
pubmed: 24582775
Transl Psychiatry. 2016 Oct 18;6(10):e924
pubmed: 27754483
Psychol Med. 2016 Jun;46(8):1735-47
pubmed: 26984533
Psychiatry Res. 2010 Jul 30;178(2):381-90
pubmed: 20483476
Front Psychol. 2015 Jun 16;6:761
pubmed: 26136697
Soc Psychiatry Psychiatr Epidemiol. 2014 Feb;49(2):169-82
pubmed: 24435092
Mol Psychiatry. 2013 Apr;18(4):497-511
pubmed: 22472876
Schizophr Res. 2004 Jun 1;68(2-3):271-81
pubmed: 15099609
Schizophr Res Cogn. 2018 Jan 28;12:11-19
pubmed: 29552508
Soc Psychiatry Psychiatr Epidemiol. 2020 May;55(5):645-657
pubmed: 31974809
PLoS One. 2016 Jun 14;11(6):e0154145
pubmed: 27300727
Nat Genet. 2016 Oct;48(10):1279-83
pubmed: 27548312
Biol Psychiatry. 2017 Mar 15;81(6):470-477
pubmed: 27765268
Psychol Med. 2019 Jun;49(8):1378-1391
pubmed: 30282569
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
Schizophr Res. 2008 Feb;99(1-3):270-3
pubmed: 18055176
Schizophr Bull. 2010 Jul;36(4):680-7
pubmed: 18953071
Psychol Med. 2021 Mar;51(4):623-633
pubmed: 32327005
Schizophr Res. 2014 Dec;160(1-3):150-6
pubmed: 25464918
Schizophr Res. 2020 Apr;218:7-13
pubmed: 31932173
Schizophr Res. 2013 Dec;151(1-3):78-84
pubmed: 24268469
Cogn Neuropsychiatry. 2013;18(6):574-93
pubmed: 23167265
JAMA Psychiatry. 2018 Jan 1;75(1):36-46
pubmed: 29214289
Schizophr Bull. 2013 Jan;39(1):77-85
pubmed: 21697150
Schizophr Bull. 2010 Sep;36(5):1009-19
pubmed: 19329561
Schizophr Res. 2016 Apr;172(1-3):177-83
pubmed: 26874869
J Insect Sci. 2003;3:34
pubmed: 15841249
Schizophr Bull. 2020 Jul 8;46(4):823-833
pubmed: 32080743
Schizophr Res. 2014 Mar;153(1-3):32-7
pubmed: 24457036
Biol Psychiatry. 2019 Jul 15;86(2):97-109
pubmed: 30737014
Nat Neurosci. 2019 Mar;22(3):343-352
pubmed: 30718901
Nat Genet. 2019 May;51(5):793-803
pubmed: 31043756
Am J Psychiatry. 2003 Oct;160(10):1768-74
pubmed: 14514489
Nature. 2009 Aug 6;460(7256):748-52
pubmed: 19571811
Br J Psychiatry. 2007 Aug;191:126-30
pubmed: 17666496
Mol Psychiatry. 2015 Apr;20(4):454-8
pubmed: 25023143
Schizophr Res. 2015 Feb;161(2-3):322-8
pubmed: 25533595
Behav Cogn Neurosci Rev. 2002 Mar;1(1):21-62
pubmed: 17715585
Am J Med Genet B Neuropsychiatr Genet. 2017 Oct;174(7):701-711
pubmed: 28608620
Nat Genet. 2016 Nov;48(11):1443-1448
pubmed: 27694958
Nat Genet. 2006 Aug;38(8):904-9
pubmed: 16862161
Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7):639-47
pubmed: 27250978
Am J Psychiatry. 2003 Apr;160(4):636-45
pubmed: 12668349
Epidemiology. 1990 Jan;1(1):43-6
pubmed: 2081237
Schizophr Res. 2015 Feb;161(2-3):392-8
pubmed: 25543332
Psychol Med. 2002 Feb;32(2):347-58
pubmed: 11866327
Lancet Psychiatry. 2019 May;6(5):427-436
pubmed: 30902669
Schizophr Res. 2014 Sep;158(1-3):105-12
pubmed: 25052782
Psychiatry Res. 2016 Dec 30;246:52-57
pubmed: 27657804
Cell. 2018 Jun 14;173(7):1705-1715.e16
pubmed: 29906448
Acta Psychiatr Scand. 2012 Jan;125(1):66-76
pubmed: 22013907
Schizophr Res. 2000 Dec 15;46(2-3):209-15
pubmed: 11120433
Lancet. 2009 Aug 22;374(9690):635-45
pubmed: 19700006
Cell. 2019 Oct 17;179(3):589-603
pubmed: 31607513
PLoS One. 2016 Jul 28;11(7):e0160056
pubmed: 27467692

Auteurs

Giada Tripoli (G)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, University of Palermo, Palermo, Italy.
Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.

Diego Quattrone (D)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, King's College London, London, UK.
Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany and National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, UK.

Laura Ferraro (L)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, University of Palermo, Palermo, Italy.

Charlotte Gayer-Anderson (C)

Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, UK.

Caterina La Cascia (C)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, University of Palermo, Palermo, Italy.

Daniele La Barbera (D)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, University of Palermo, Palermo, Italy.

Crocettarachele Sartorio (C)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, University of Palermo, Palermo, Italy.

Fabio Seminerio (F)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, University of Palermo, Palermo, Italy.

Victoria Rodriguez (V)

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.

Ilaria Tarricone (I)

Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna , Bologna, Italy.

Domenico Berardi (D)

Department of Biomedical and NeuroMotor Sciences, Psychiatry Unit, Alma Mater Studiorum Università di Bologna , Bologna, Italy.

Stéphane Jamain (S)

Institut National de la Santé et de la Recherche Médicale, Faculté de Médecine, Université Paris-Est, Creteil, France.

Celso Arango (C)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health. Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.

Andrea Tortelli (A)

Etablissement Public de Santé Maison Blanche, Paris, France.

Pierre-Michel Llorca (PM)

Université Clermont Auvergne, Clermont-Ferrand, France.

Lieuwe de Haan (L)

Department of Psychiatry, Early Psychosis Section, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Eva Velthorst (E)

Department of Psychiatry, Early Psychosis Section, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, NY.

Julio Bobes (J)

Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, Spain.

Miquel Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital clinic, Department of Medicine, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.

Julio Sanjuán (J)

Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Valencia, Spain.

Jose Luis Santos (J)

Department of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz", Cuenca, Spain.

Manuel Arrojo (M)

Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Spain.

Cristina Marta Del-Ben (C)

Division of Psychiatry, Department of Neuroscience and Behaviour, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.

Paulo Rossi Menezes (P)

Department of Preventive Medicine, Faculdade de Medicina, Universidade of São Paulo, São Paulo, Brazil.

Els van der Ven (E)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.
Vrije Universiteit Amsterdam, Department of Clinical, Neuro- and Developmental Psychology.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, Cambridge, UK.
CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK.

Hannah E Jongsma (HE)

Psylife Group, Division of Psychiatry, University College London, London, UK.

James B Kirkbride (JB)

Psylife Group, Division of Psychiatry, University College London, London, UK.

Sarah Tosato (S)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.

Antonio Lasalvia (A)

Section of Psychiatry, Azienda Ospedaliera Universitaria Integrata di Verona , Verona, Italy.

Alex Richards (A)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.

Michael O'Donovan (M)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.

Bart P F Rutten (BPF)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.

Jim van Os (J)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, University of Palermo, Palermo, Italy.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department Psychiatry, Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands.

Craig Morgan (C)

Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, UK.

Pak C Sham (PC)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Centre for Genomic Sciences, Li KaShing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Marta Di Forti (M)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, King's College London, London, UK.

Robin M Murray (RM)

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.

Graham K Murray (GK)

Department of Psychiatry, University of Cambridge, Cambridge, UK.
CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK.
Institute for Molecular Bioscience, University of Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH